comparemela.com

Latest Breaking News On - Hemmelrather weg - Page 1 : comparemela.com

Form F-6 POS Biofrontera AG/ADR Filed by: BANK OF NEW YORK / ADR DIVISION

Form F-6 POS Biofrontera AG/ADR Filed by: BANK OF NEW YORK / ADR DIVISION
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

PTA-News: Biofrontera AG: Biofrontera improves the brand protection of Ameluz®-PDT in the US and strengthens internal quality assurance structures

Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp

Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24 7 million

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million Biofrontera AGFebruary 26, 2021 GMT Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, announces the closing of the capital increase resolved by the annual general meeting on May 28, 2020. The capital increase was carried out by way of a subscription rights offering to existing shareholders of Biofrontera AG under German law. Unsubscribed shares were placed in the course of a public offering of American Depositary Shares (“ADS” and “ADS Offering”) in the United States. The Company raised total gross proceeds of approximately EUR 24.7 million.

Biofrontera AG: Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24 7 million

Business news for the stock market Biofrontera AG: Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million Leverkusen (pta046/26.02.2021/15:20) - Leverkusen, Germany, February 26, 2021- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) ( Biofrontera or the Company ), an international biopharmaceutical company, announces the closing of the capital increase resolved by the annual general meeting on May 28, 2020. The capital increase was carried out by way of a subscription rights offering to existing shareholders of Biofrontera AG under German law. Unsubscribed shares were placed in the course of a public offering of American Depositary Shares ( ADS and ADS Offering ) in the United States. The Company raised total gross proceeds of approximately EUR 24.7 million.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.